1
|
Goretzki A, Zimmermann J, Rainer H, Lin YJ, Schülke S. Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment - Disease-Specific Findings (Part 1). Curr Allergy Asthma Rep 2023; 23:29-40. [PMID: 36441389 PMCID: PMC9832111 DOI: 10.1007/s11882-022-01057-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/14/2022] [Indexed: 11/29/2022]
Abstract
PURPOSE OF REVIEW Recent high-level publications have shown an intricate connection between immune effector function and the metabolic state of the respective cells. In the last years, studies have begun analyzing the metabolic changes associated with allergies. As the first part of a two-article series, this review will briefly summarize the basics of immune metabolism and then focus on the recently published studies on metabolic changes observed in allergic patients. RECENT FINDINGS In the last 3 years, immune-metabolic research in allergology had a clear focus on asthma with some studies also reporting findings in food allergy and atopic dermatitis. Current results suggest asthma to be associated with a shift in cellular metabolism towards increased aerobic glycolysis (Warburg metabolism), while also displaying substantial changes in fatty acid- and amino acid metabolism (depending on investigated patient collective, asthma phenotype, and disease severity). Understanding immune-metabolic changes in allergies will allow us to (I) better understand allergic disease pathology and (II) modulate immune-metabolic pathways to improve allergy treatment.
Collapse
Affiliation(s)
- A. Goretzki
- Vice President’s Research Group 1: Molecular Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany
| | - J. Zimmermann
- Vice President’s Research Group 1: Molecular Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany
| | - H. Rainer
- Vice President’s Research Group 1: Molecular Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany
| | - Y.-J. Lin
- Vice President’s Research Group 1: Molecular Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany
| | - Stefan Schülke
- Vice President's Research Group 1: Molecular Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Germany.
| |
Collapse
|
2
|
Larranaga N, Albertazzi FJ, Fontecha G, Palmieri M, Rainer H, van Zonneveld M, Hormaza JI. A Mesoamerican origin of cherimoya (Annona cherimola Mill.): Implications for the conservation of plant genetic resources. Mol Ecol 2017; 26:4116-4130. [PMID: 28437594 DOI: 10.1111/mec.14157] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 04/13/2017] [Accepted: 04/14/2017] [Indexed: 01/13/2023]
Abstract
Knowledge on the structure and distribution of genetic diversity is a key aspect to plan and execute an efficient conservation and utilization of the genetic resources of any crop as well as for determining historical demographic inferences. In this work, a large data set of 1,765 accessions of cherimoya (Annona cherimola Mill, Annonaceae), an underutilized fruit tree crop native to the Neotropics and used as a food source by pre-Columbian cultures, was collected from six different countries across the American continent and amplified with nine highly informative microsatellite markers. The structure analyses, fine representation of the genetic diversity and an ABC approach suggest a Mesoamerican origin of the crop, contrary to previous reports, with clear implications for the dispersion of plant germplasm between Central and South America in pre-Columbian times. These results together with the potential distribution of the species in a climatic change context using two different climate models provide new insights for the history and conservation of extant genetic resources of cherimoya that can be applied to other currently underutilized woody perennial crops.
Collapse
Affiliation(s)
- N Larranaga
- Instituto de Hortofruticultura Subtropical y Mediterránea La Mayora (IHSM-UMA-CSIC), Algarrobo-Costa, Málaga, Spain
| | - F J Albertazzi
- Centro de Investigación en Biología Celulary Molecular (CIBCM), Universidad de Costa Rica, San José, Costa Rica
| | - G Fontecha
- Microbiology Research Institute, Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Honduras
| | - M Palmieri
- Universidad del Valle de Guatemala, Ciudad de Guatemala, Guatemala
| | - H Rainer
- University of Vienna, Vienna, Austria
| | - M van Zonneveld
- Bioversity International, Costa Rica Office, Turrialba, Costa Rica
| | - J I Hormaza
- Instituto de Hortofruticultura Subtropical y Mediterránea La Mayora (IHSM-UMA-CSIC), Algarrobo-Costa, Málaga, Spain
| |
Collapse
|
3
|
Mader R, Rainer H, Steger G. Biochemical Modulation of Fluoropyrimidines: Preclinical and Clinical Studies. Oncol Res Treat 2009. [DOI: 10.1159/000218440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Jakesz R, Steger G, Rainer H. The Rationale and Value of Preoperative Treatment Modalities in Patients with Locally Advanced Breast Carcinoma. Oncol Res Treat 2009. [DOI: 10.1159/000216980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
5
|
Rainer H, Höcker P, Pittermann E, Moser K. Säulenchromatographische Anreicherung von DNA-Polymerase-Aktivitäten bei Leukämie. Acta Haematol 2009. [DOI: 10.1159/000208350] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
6
|
Gaggl A, Rainer H, Chiari FM. Horizontal distraction of the anterior maxilla in combination with bilateral sinuslift operation--preliminary report. Int J Oral Maxillofac Surg 2005; 34:37-44. [PMID: 15617965 DOI: 10.1016/j.ijom.2004.03.008] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In many cases alveolar ridge atrophy causes severe alveolar ridge deficiency in horizontal and vertical direction. In cases of severe atrophy of the edentulous maxilla a maxillary retrognathism results. In this article, a new technique of solving this problem prior to implant placement is described. In six patients with severe atrophy of the edentulous maxilla a sinuslift operation and placement of dental implants were carried out in the posterior maxilla. In the anterior part of the maxilla a segmental split osteotomy and placement of two miniplate distractors were performed. One week after surgery distraction started with a distraction speed of 0.5 mm a day until a clinical correct position of the anterior maxilla resulted. Then, the stabilisation period of 12 weeks followed before the distractors were removed and two to four implants were placed in the anterior distracted maxilla. After a second healing period of 4 months the implants were used for loading by a fixed prosthetic superstructure. Six patients were treated by this regime and 58 implants were placed. All implants were loaded by a fixed prosthesis. Distraction was performed without disturbances. Three months after healing new bone was formed in the distraction gap. There was no implant loss. An aesthetic satisfying superstructure with good red and white aesthetics was achieved together with a correct interalveolar relation. Distraction of the anterior part of the maxilla in combination with sinuslift operation is an alternative technique for correction of interalveolar incongruences in the edentulous maxilla and augmentation prior to implant placement.
Collapse
Affiliation(s)
- A Gaggl
- Department of Oral and Maxillofacial Surgery, General Hospital/LKH Klagenfurt, St. Veiterstr. 47, A-9020 Klagenfurt, Austria.
| | | | | |
Collapse
|
7
|
Abstract
Ascending chlamydial infections have been thought to be an infective cause of prostatitis for the last three decades. Unfortunately, the definitive association between isolation of an infective agent and its prostatic origin is limited by various factors, although modern techniques of molecular biology for identification of the microorganisms are available. Two major problems are: (1) diagnostic material passing the urethra may reflect only urethral contamination, (2) prostatic biopsy specimens from the gland may also contain urethral material. The ejaculate has the same limitations, and an ideal test for detection of Chlamydia species in ejaculate specimens is not available yet. Investigations for local chlamydial IgA-antibodies may be useful; the overlap with Chlamydia pneumoniae and Chlamydia psittaci means a clear differentiation on an type-specific basis is necessary, which is normally provided by the 'elaborate' microimmunofluorescence test. Modern p-ELISAs using major outer membrane protein parts as antigens may deliver identical results in the future. In the follow-up of standardized prostatitis patients, a combination of such urological tests in EPS and seminal plasma combined with genital chlamydial DNA material, may further elucidate the chlamydial aetiology of prostate infection.
Collapse
Affiliation(s)
- W Weidner
- Department of Urology, Universitätsklinikum Giessen, Rudolf-Buchheim-Strasse 7, D-35392 Giessen, Germany.
| | | | | | | | | |
Collapse
|
8
|
Abstract
Seven patients with severe periodontitis that had resulted in loss of alveolar ridge bone were treated by tooth extraction followed by immediate insertion of an implant distraction device. After successful distraction and bony healing the implant was used to fit a prosthesis.
Collapse
Affiliation(s)
- A Gaggl
- Department of Oral and Maxillofacial Surgery, University Hospital Graz, Austria.
| | | | | | | |
Collapse
|
9
|
Gaggl A, Schultes G, Rainer H, Kärcher H. [Histological and histomorphometric results of implantation of dental implants by early and late implantation]. Mund Kiefer Gesichtschir 2000; 4:278-84. [PMID: 11092179 DOI: 10.1007/s100060000209] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In this study, a histologic and histomorphometric analysis of delayed and immediate-placed implants was performed. An implantation of 16 self-cutting conical titanium screw implants was carried out in 8 beagle dogs. Of these implants, 8 were placed immediately after extraction of the second premolar and 8 implants were placed after 6 months of healing after extraction. For dynamic histomorphometry, fluorochrome bone markers were injected at two different times prior to euthanasia. The specimens were examined macroscopically and microscopically 8 months after implantation. A histologic, dynamic, and static histomorphometry was performed with the aid of different computer programs. A mean surface of osseointegration of 75.7% and a mean soft tissue implant contact surface of 24.2% was seen in immediate-placed implants. For delayed implantation, an osseointegrated surface of 80.7% and a soft tissue covering of 19.3% was examined. The fibrogenic structures in the cervical implant part were more dense and there were more adhesive epithelial elements (hemidesmosomes) around delayed implants. The result of the dynamic and static histomorphometry showed no significant differences in the two groups (P < 0.1). In conclusion, it can be stated that a new steady-state of the soft and hard tissue around dental implants was seen 8 months after implant insertion in both groups. There was a pseudoankylotic healing in the osseous part. The lower level of osseointegration in immediate-placed implants was caused by early resorption of bone in the crestal part. Thus, a larger part of the implant was surrounded by soft tissue and a long epithelial attachment resulted.
Collapse
Affiliation(s)
- A Gaggl
- Klinische Abteilung für Mund-, Kiefer- und Gesichtschirurgie, Universität Graz.
| | | | | | | |
Collapse
|
10
|
Locker GJ, Kapiotis S, Veitl M, Mader RM, Stoiser B, Kofler J, Sieder AE, Rainer H, Steger GG, Mannhalter C, Wagner OF. Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br J Haematol 1999; 105:912-9. [PMID: 10554800 DOI: 10.1046/j.1365-2141.1999.01453.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Treatment with intravenous recombinant human interleukin-2 (rh IL-2) is frequently accompanied by the capillary leak syndrome and disturbances of the coagulation system. Although the exact mechanisms are still not fully understood, the involvement of the endothelium is proven. This investigation aimed to elucidate more precisely the role of the endothelium in the generation of IL-2-based side-effects. In nine tumour patients receiving intravenous rh IL-2, parameters characterizing endothelial cell activation as well as activation of the coagulation system were evaluated. A significant increase of the circulating endothelial leucocyte adhesion molecule-1 (cELAM-1) and the vasoconstrictor peptide endothelin-1 (ET-1) was observed (P<0.05), indicating activation of endothelial cells. The simultaneous increase of tissue-plasminogen activator and plasminogen activator inhibitor type-1 during therapy (P<0.05) corroborated this observation. A decrease in platelet count parallelled by an increase of fibrin degradation products, the prolongation of partial thromboplastin time, and the decrease of fibrinogen (P<0.05) suggested the development of disseminated intravascular coagulation (DIC), induced by activated endothelium and intensified by transient hepatic failure. We concluded that activation of the endothelium mediated by IL-2 was accompanied by a loss of endothelial integrity and capillary leak. The activated endothelium can trigger DIC via activation of the coagulation cascade. The increased ET-1 might act as an endogenous counter-regulator of the disadvantageous haemodynamic side-effects induced by IL-2.
Collapse
Affiliation(s)
- G J Locker
- Department of Internal Medicine I, University Hospital of Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Affiliation(s)
- H. Rainer
- Institute for Safety Research and Reactor Technology, Forschungszentrum Jülich GmbH, D-52425 Jülich, Germany
| | - J. Fachinger
- Institute for Safety Research and Reactor Technology, Forschungszentrum Jülich GmbH, D-52425 Jülich, Germany
| |
Collapse
|
12
|
Mader RM, Sieder AE, Braun J, Rizovski B, Kalipciyan M, Mueller MW, Jakesz R, Rainer H, Steger GG. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro. Biochem Pharmacol 1997; 54:1233-42. [PMID: 9416974 DOI: 10.1016/s0006-2952(97)00330-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Cellular resistance to 5-fluorouracil (5-FU) is not completely understood. Since 5-FU shares the pyrimidine pathway with the physiological pyrimidines, we investigated the relationship between fluoropyrimidine metabolism, nucleic acid uptake and cytotoxicity of 5-FU in eight colon tumour cell lines including 5-FU-resistant subclones. The cytotoxicity of 5-FU was increased up to 423-fold when the anabolites 5-fluorouridine (FUrd), 5-fluorodeoxyuridine (FdUrd), and 5-fluorodeoxyuridine monophosphate (FdUMP) were compared with the parent drug in vitro. The enzymes uridine phosphorylase and thymidine phosphorylase were predictive for the cytotoxicity of 5-FU in 5/7 cell lines. Inhibition of uridine phosphorylase and thymidine phosphorylase by antisense strategies effectively antagonised 5-FU, abolishing 84% and 79% of its toxicity. The importance of thymidine phosphorylase was supported by a highly restricted enzyme activity in 5-FU-resistant cells. In 5-FU naive cells, a stimulating effect of 5-FU on thymidylate synthase mRNA and ribonucleotide reductase mRNA expression was observed. In these cells, antisense oligonucleotides to ribonucleotide reductase significantly reduced cell growth. Downregulation of ribonucleotide reductase mRNA in 5-FU-resistant subclones suggests different mechanisms in primary and secondary resistance to 5-FU. Most of the intracellular 5-FU was selectively incorporated into RNA (range: 45-91%) and generally spared DNA (range: 0.2-11%). In synthesising our data, we conclude that drug resistance could be overwhelmed through bypassing limiting steps in the activation of 5-FU. In the majority of colonic tumours, the activity of uridine phosphorylase and thymidine phosphorylase may have prognostic relevance for the cytotoxicity of 5-FU in vitro.
Collapse
Affiliation(s)
- R M Mader
- Department of Internal Medicine I, University of Vienna, Austria.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Mader RM, Rizovski B, Steger GG, Wachter A, Kotz R, Rainer H. Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Arch Environ Health 1996; 51:310-4. [PMID: 8757411 DOI: 10.1080/00039896.1996.9936030] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Methotrexate is a therapeutic agent used widely for osteosarcoma. We used an extremely sensitive high-performance liquid-chromatography assay to evaluate 112 urine samples obtained from 28 hospital employees during high-dose therapy with methotrexate and during routine care of patients. The highest cumulative urinary excretion was observed when methotrexate infusions were handled in a workbench from which a portion of filtered air was emitted into the room. Remarkable urine contaminations were identified for personnel, including 1 administrative employee who had "stood by" for 2 h in the room where infusions were prepared. Lower methotrexate concentrations were detected in the urine of nurses whose exclusive function was to care for patients. The urine burden in oncologic nurses decreased after a central pharmacy unit was installed. Methotrexate was excreted in the sweat of patients who were under high-dose therapy, and its elimination half-life was 11.1 h (mean maximal concentration = 1.7 micrograms/ml [n = 51). The maximal burden in spontaneous vomit from these patients was 441.5 micrograms/ml, and it declined to 0.24 micrograms/ml 19.5 h after infusion was completed. No methotrexate was detected in personnel who prepared 20-g methotrexate infusions in the central pharmacy unit. We demonstrated that occupational safety depended not only on technical precautions, but on the skills of specifically trained personnel.
Collapse
Affiliation(s)
- R M Mader
- Department of Internal Medicine I, Division of Oncology, University of Vienna, Austria
| | | | | | | | | | | |
Collapse
|
14
|
Blöchl-Daum B, Mader R, Millesi W, Lang S, Rainer H, Eglmeier R, Müller M, Zanaschka G, Eichler HG. First-pass uptake of methotrexate after intra-arterial bolus injection in human head and neck cancers. Eur J Clin Invest 1996; 26:371-5. [PMID: 8796363 DOI: 10.1046/j.1365-2362.1996.119302.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The aim of this study was to quantify first-pass uptake of methotrexate into tumour and healthy tissue after intra-arterial (i.a.) injection in patients with head and neck cancers. Twenty-one patients were studied; during surgery, a bolus injection of 10 mg of 3H-labelled methotrexate was administered into the tumour-supplying artery. At 15-20 s after injection, and again 2-3 h later, a biopsy of the tumour and of surrounding healthy tissue was taken and radioactivity was measured. In 8 of 17 pretreated patients the biopsy specimens contained no tumour cells. In tumour-bearing patients, radioactivity in tumour was three times higher than in healthy tissue (P = 0.006). In tumour-negative patients there was no difference in activity between the two biopsy sites (P = 0.889). However, after 2-3 h the concentration of methotrexate in all surgical specimens returned to near background level and the initial difference between tumour-positive and tumour-negative samples was lost. Our results show that i.a. injection of methotrexate does not necessarily lead to high tumour cell exposure.
Collapse
Affiliation(s)
- B Blöchl-Daum
- Department of Clinical Pharmacology, Vienna University Hospital, Austria
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Mader RM, Steger GG, Rizovski B, Djavanmard MP, Scheithauer W, Jakesz R, Rainer H. Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br J Clin Pharmacol 1995; 40:209-15. [PMID: 8527281 PMCID: PMC1365099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
1. The pharmacokinetics and toxicity of racemic 5-methyltetrahydrofolic (rac-5-MTHF) acid after i.v. infusion were investigated in 18 patients with advanced colorectal cancer. Doses of 100-600 mg rac-5-MTHF/m2 were administered over 2 h together with a bolus of 500 mg/m2 5-fluorouracil (5-FU) as a midpoint injection. 2. The pharmacokinetics of both diastereoisomers were linear in the range from 100-600 mg 5-MTFH/m2. Independent of the administered dose, the maximal plasma concentration of [R]-5-MTHF was nearly twice that of [S]-5-MTHF. The elimination of [S]-5-MTHF from plasma was considerably faster than that of the [R]-isomer (elimination half-life: 3.1 +/- 1.0 h vs 8.3 +/- 3.2 h). No metabolites were detected in plasma and in urine samples. 3. The plasma protein binding was stereoselective ([R]-5-MTHF bound: 88.2 +/- 2.7%; [S]-5-MTHF bound: 59.9 +/- 6.8%; P < 0.001), causing a significantly higher renal clearance for [S]-5-MTHF when compared with the [R]-isomer (37.5 +/- 23.7 ml min-1 vs 12.7 +/- 11.2 ml min-1, P < 0.001). There was no dose dependence, but gender influenced renal clearance (CLren[R]-5-MTHF: male vs female: 20.5 +/- 14.5 ml min-1 vs 7.8 +/- 4.7 min-1, P = 0.03; CLren [S]-5-MTHF: male vs female: 57.2 +/- 21.7 ml min-1 vs 25.7 +/- 16.2 ml min-1, P = 0.006). 4. Toxic side effects of the combination 5-FU/5-MTHF were rare and generally mild, and included stomatitis, nausea/emesis, diarrhoea, anaemia, leukopenia, and thrombocytopenia. 5. In combination with 500 mg 5-FU/m2 a single dose of 600 mg rac-5-MTHF/m2 can safely be administered to patients with colorectal cancer. A similar therapeutic benefit of 5-MTHF to folinic acid in the biochemical modulation of 5-FU is supported by the comparison of in vitro and in vivo data.
Collapse
Affiliation(s)
- R M Mader
- Department of Internal Medicine, University of Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
16
|
Locker GJ, Simonitsch I, Mader RM, Warlamides E, Gnant MF, Jakesz R, Rainer H, Steger GG. Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity? Breast Cancer Res Treat 1995; 34:213-9. [PMID: 7579485 DOI: 10.1007/bf00689712] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The application of recombinant colony stimulating factors for chemotherapy induced granulocytopenia is becoming common in clinical oncology. Here we report on localized cutaneous side effects after subcutaneous administration of recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in 11 patients with breast cancer receiving cytostatic treatment. Seven patients suffering from inflammatory breast cancer received cytostatic chemotherapy with mitoxantrone/cyclophosphamide, whereas four patients suffering from noninflammatory breast cancer received high-dose epirubicin/cyclophosphamide, respectively. rh GM-CSF was applicated subcutaneously in a dose of 5 micrograms/kg/d for at least ten days. In all patients, sharply demarked, maculous itching and burning erythemas restricted to the injection sites occurred after three to four injections of rh GM-CSF. These eruptions cleared within 2 to 3 weeks, but reappeared after reexposure to rh GM-CSF. In contrast to previous sporadic reports, no generalized erythemas were observed. Because of this unexpected and subjectively intolerable side effect, rh GM-CSF administration had to be interrupted in all patients. Histopathological findings revealed skin infiltration with lymphocytes, monocytes/macrophages, neutrophils, and occasionally eosinophils, respectively. Since GM-CSF is known to alter immune functions, it seems likely that the eruptions were at least in part due to local immune reactions.
Collapse
Affiliation(s)
- G J Locker
- Department of Internal Medicine, University of Vienna, Austria
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Locker GJ, Mader RM, Braun J, Sieder AE, Marosi C, Rainer H, Jakesz R, Steger GG. New mucin-like cancer-associated antigens (CA M 26, CA M 29 and CA 549) and a new proliferation marker (TPS) in patients with primary or advanced breast cancer. Oncology 1995; 52:140-4. [PMID: 7854774 DOI: 10.1159/000227445] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In patients with breast cancer no tumor markers giving satisfactory results have been found yet. The aim of our investigation was to compare the usefulness of newly developed tumor markers with the most common used carcinoembryonic antigen and cancer antigen (CA) 15-3. We evaluated the concentrations of carcinoma-associated antigen (CA) 549, carcinoma-associated mucin antigen (CA M) 26 and CA M 29, and the proliferation markers tissue polypeptide antigen (TPA) and tissue polypeptide-specific antigen (TPS) in 84 breast cancer patients with disease progression and in 69 patients with no evidence of disease after surgery for breast cancer. Using receiver-operating characteristic curves (ROC curves) we were able to demonstrate increased sensitivity and specificity of all tested tumor markers in patients with metastatic disease compared with local disease. In our investigation TPA is superior to TPS in all disease states. In local disease, none of the tested markers shows satisfying results. In metastatic disease, the new mucin markers CA M 26 and CA M 29 show slightly better results than CA 15-3 although their ROC curves are nearly congruent. CA 549 is exceeded by the other mucin markers. The best results in this investigation were obtained with CA M 29. The overall results concerning the detection of small tumor masses (i.e. local disease) were unsatisfactory.
Collapse
Affiliation(s)
- G J Locker
- Department of Internal Medicine I, University of Vienna, Austria
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Heys SD, Eremin O, Ruggeri EM, Pein F, Rainer H, Oskam R, de Peuter RA, Palmer PA, Franks CR. A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. Eur J Cancer 1995; 31A:19-25. [PMID: 7695972 DOI: 10.1016/0959-8049(94)00360-h] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
135 patients with locally advanced or metastatic colorectal cancer were entered into a phase III trial evaluating the efficacy of chemoimmunotherapy [recombinant interleukin 2 (rIL2)/5-fluorouracil (5-FU) and leucovorin (LV)] versus chemotherapy alone (5-FU/LV). A cycle of chemoimmunotherapy comprised a constant intravenous infusion of rIL2 at a dose of 18 x 10(6) U/m2/24 h for 120 h, followed by three bolus injections of 5-FU (600 mg/m2) and LV (25 mg/m2) at weekly intervals. Patients receiving chemotherapy alone received 5-FU/LV at the same dose at weekly intervals for 6 weeks followed by a rest period of 2 weeks, constituting one cycle of therapy. A maximum of 6 months therapy was given in both arms of the study. The response rates (complete and partial responses) were 17% in patients receiving rIL2/5-FU/LV versus 16% in those in the 5-FU/LV arm of the study. Median survival and progression-free survival were comparable for the two groups of patients, although there was a trend for a prolongation of survival in patients receiving chemoimmunotherapy compared with chemotherapy alone, beyond 12 months. Retrospective subgroup analyses revealed a significantly increased survival in poor prognosis patients (ECOG 1) treated with rIL2/5-FU/LV when compared to those receiving chemotherapy alone. Therefore, further studies evaluating the dose and duration of chemoimmunotherapy in patients with metastatic colorectal cancer seem warranted.
Collapse
Affiliation(s)
- S D Heys
- University Department of Surgery, Aberdeen, U.K
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
The protein binding of the tetrahydrofolates folinic acid (FA) and its metabolite 5-methyltetrahydrofolic acid (5-MTHF) to human serum albumin (HSA) is stereoselective. At therapeutically relevant concentrations of tetrahydrofolate (range, 5-100 microM), the protein binding was stereoselective to the (R)-isomers of FA and 5-MTHF. The binding of (R)-FA and (R)-5-MTHF was saturated at a concentration of 7% HSA [(R)-tetrahydrofolate bound, ca. 80%]. In contrast to (S)-FA, which was not bound to HSA, (S)-5-MTHF was bound to 45% under physiological conditions. (R)-FA did not influence the protein binding of (S)-FA. Hypoalbuminemia is common in patients with advanced colorectal cancer and affects differentially the protein binding of the diastereoisomers of FA and 5-MTHF. Thus, an influence on the biochemical modulation of 5-fluorouracil by tetrahydrofolates should be taken into consideration.
Collapse
Affiliation(s)
- R M Mader
- Department of Internal Medicine I, University of Vienna, Austria
| | | | | | | | | |
Collapse
|
20
|
Steger GG, Mader RM, Djavanmard MP, Gnant MF, Locker G, Marosi C, Rainer H, Jakesz R. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. J Cancer Res Clin Oncol 1994; 120:314-8. [PMID: 8126062 DOI: 10.1007/bf01236390] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In an attempt to evaluate the feasibility of 5-fluorouracil (FU) treatment modulated by (R,S)-leucovorin (LV) and interferon alpha (IFN alpha) in patients with advanced colorectal cancer, we conducted a phase I trial with increasing doses of subcutaneous IFN alpha (3 x 1 x 10(6) U, 3 x 3 x 10(6) U, 3 x 3 x 10(6) U, 3 x 5 x 10(6) U and 3 x 10 x 10(6) U/week) and 500 mg/m2 LV i.v. as a 2-h infusion with 600 mg/m2 FU i.v. as a midpoint injection. Unacceptable side-effects occurred in all 3 patients at the highest dose level of IFN alpha, while toxicity was tolerable at 3 x 5 x 5 x 10(6) U IFN alpha/week. Thus, this dose was defined as the maximal tolerable dose for IFN alpha in combination with FU and LV. In a subsequent phase II study a total of 83 treatment courses (median: 2.8, range: 2-10) were administered to 30 evaluable patients. Side-effects were acceptable with no WHO grade IV toxicities. Grade III toxicities consisted in thrombopenia (2/30), stomatitis (2/30), diarrhoea (3/30) and nausea/vomiting (4/30). After a median observation time of 17 months (range: 8-22 months), no complete remission was observed and 9 patients experienced a partial response lasting for a median of 6.6 months (range: 3-13+ months), for an overall response rate of 30% (95% confidence interval: 15%-49%). These results show that the described regiment of FU doubly modulated by LV and IFN alpha is active in colorectal cancer and can be safely administered in an out patient setting with acceptable toxicity. Thus, this regimen is suitable to be used for further evaluation in clinical trials.
Collapse
Affiliation(s)
- G G Steger
- Department of Internal Medicine I, University of Vienna, Austria
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Stühlinger M, Helmer H, Dobianer K, Hruza C, Rainer H, Locker G, Spona J. Clinical therapy and HER-2 oncogene amplification in breast cancer: chemo- vs radiotherapy. J Steroid Biochem Mol Biol 1994; 49:39-42. [PMID: 7911677 DOI: 10.1016/0960-0760(94)90298-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
One hundred and five breast cancer patients with stage T3/4, N+/-, Mo were treated at random either with a pre- and postoperative chemotherapy (A) (5-drug-combination + tamoxifen) or with a pre- and postoperative radiotherapy (B). Paraffin embedded tissue samples were prepared from tumor material taken by biopsy prior to therapy as well as at surgery from patients of both groups to estimate the HER-2 oncogene copy numbers before and after treatment. In 53 and 50% of the pretherapeutic samples the HER-2 gene was amplified in groups A and B, respectively. In the post-therapeutic group 60% of the chemotherapy and 48% of the radiotherapy patients, respectively, had low or high HER-2 oncogene copy numbers. In addition, HER-2 amplification before and after therapy was estimated in 28 patients. An increase of oncogene copy numbers could be detected in 21% of the chemotherapy patients, and a decrease was noted in 11%. No radiotherapy patient showed a rise, but 11% a loss of copy numbers. Although amplification of HER-2 oncogene was not found to be associated with overall survival as it was in many studies before, it could still be a predictor of clinical outcome and the cause of mammary carcinomas developing into stage T3/4.
Collapse
Affiliation(s)
- M Stühlinger
- Ludwig Boltzmann Institute for Experimental Endocrinology, Department of Cellular Endocrinology, Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
22
|
Mader RM, Steger GG, Rizovski B, Sieder AE, Locker G, Gnant MF, Jakesz R, Rainer H. Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. Br J Clin Pharmacol 1994; 37:243-8. [PMID: 8198932 PMCID: PMC1364754 DOI: 10.1111/j.1365-2125.1994.tb04270.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
1. The pharmacokinetics of [R]-leucovorin ([R]-LV), [S]-leucovorin ([S]-LV) and the circulating metabolite [S]-5-methyltetrahydrofolate ([S]-5-MTHF) were studied after administration of racemic LV and [S]-LV in 21 subjects. 2. After intravenous infusion of 600 mg m-2 rac-LV (group 1, n = 7) or 300 mg m-2 [S]-LV (group 3, n = 7), the decay of [S]-LV in plasma was biexponential with a distribution half-life of 0.8 to 1 h and an elimination half-life of 11 to 23 h. When rac-LV was administered as a 2 h i.v. infusion (400 mg m-2) following a loading dose of 200 mg m-2 (group 2, n = 7), the plasma concentrations of [R]-LV and [S]-5-MTHF decayed monoexponentially with mean (+/- s.d.) half-lives of 10 +/- 3 h and 7 +/- 2 h, respectively. 3. The AUC of [S]-5-MTHF was significantly higher after infusion of 300 mg m-2 [S]-LV than after infusion of 600 mg m-2 rac-LV (83 +/- 22 micrograms ml-1 h vs 53 +/- 22 micrograms ml-1 h; P = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- R M Mader
- Department of Internal Medicine I, University of Vienna, Austria
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Mader RM, Steger GG, Braun J, Rainer H. Comparison of an immunoradiometric and an immunoluminometric assay for the evaluation of the tumour associated antigens CA 19-9 and CA 125. Eur J Clin Chem Clin Biochem 1994; 32:85-90. [PMID: 8003582 DOI: 10.1515/cclm.1994.32.2.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We evaluated the levels of CA 19-9 and CA 125 in the sera of healthy individuals, patients with non-neoplastic diseases known to produce elevated serum concentrations of CA 19-9 and CA 125, and patients with malignant tumours. The serum concentrations determined with an immunoradiometric assay (IRMA) and an immunoluminometric assay (ILMA) were compared. The accuracy was determined (as far as this is possible in the absence of reference method values), as well as the precision (intra-assay variation and inter-assay variation), using internal and external controls. The serum concentrations were comparable in both test systems (coefficient of correlation, Kendall's Tau of CA 19-9: 0.88, p < 0.001; CA 125: 0.87, p < 0.001). The linearity of both assays was excellent when serum samples were diluted (r > 0.98 in all assays tested). The intra-assay variation of CA 19-9 IRMA was less than that of CA 19-9 ILMA, and was comparable for CA 125 in both assays. The coefficients of variation of duplicates were nearly independent of the antigen concentration within the range 20-1000 kU/l (mean CV CA 19-9: 3.7% and 3.9% for IRMA and ILMA, respectively; mean CV CA 125: 3.9% and 5.6% for IRMA and ILMA, respectively). In the assay of external controls, the performance of the IRMAs was found to be slightly better than that of the ILMAs, but it was not satisfactory. We conclude that, with some improvements in quality control, luminescence assays are a possible alternative to isotopic assays in the clinical laboratory.
Collapse
Affiliation(s)
- R M Mader
- Onkologisches Labor, Universitätsklinik für Innere Medizin I, Wien, Austria
| | | | | | | |
Collapse
|
24
|
Rainer H. Prospective randomized clinical trial of primary treatment in breast cancer stages T3/4, N+/-, MO. Chemotherapy vs. radiotherapy. Arbeitskreis für Perioperative Chemotherapie. Anticancer Res 1993; 13:1917-23. [PMID: 8267401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
209 patients entered a randomized trial. We compared a) pre- and postoperative chemotherapy (= treatment A) [5-drug combination chemotherapy+tamoxifen] versus b) pre- and postoperative radiotherapy (= treatment B). Nonresponders to preoperative chemotherapy were << crossed over >> to postoperative radiotherapy. The study was started in 1983. We now report on 8 years of results. The reduction in tumor size following preoperative treatment was comparable in both legs of the study. No differences were seen with regard to the response of patients with primary tumors or axillary lymph node involvement. Remission rates for treatments A and B were around 60%. In isolated cases the extent of mastectomy could be reduced as a result of preoperative treatments (breast conserving surgery was done in selected cases). While the initially large tumor size often defied even an extended radical operation, the tumor reduction achieved by prior treatment permitted the removal of macroscopically visible tumor tissue by radical surgery using Rotter's procedure. Relapse-free survival (RFS) and overall survival (OAS) on chemotherapy (N = 76) proved to be significantly superior in treatment A (chemotherapy) compared to B (radiotherapy) (N = 75) [(p for A:B RFS = 0.018) (p for A:B OAS = 0.047)]. RFS for << responders >> to chemotherapy was 65% (N = 47) and only 20% (N = 29) for non-responders (p responders vs. non-responder = 0.005). OAS for responders in group A was 79%, and for non-responders 24% (p = 0.005). OAS in group B (radiotherapy) was only 25%. (p A:B = 0.047).
Collapse
Affiliation(s)
- H Rainer
- Medizinische Univ. Klinik I, Wien, Austria
| |
Collapse
|
25
|
Ulsperger E, Rainer H, Locker G, Vetterlein M, Schiessel R, Hofbauer F, Armbruster C, Depisch D, Politzer P, Dinstl K. Adjuvant vaccination in colorectal carcinoma. Ann N Y Acad Sci 1993; 690:360-3. [PMID: 8368756 DOI: 10.1111/j.1749-6632.1993.tb44031.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- E Ulsperger
- Institute for Tumorbiology & Cancer Research, University of Vienna, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Mader RM, Rizovski B, Steger GG, Rainer H, Proprentner R, Kotz R. Determination of methotrexate in human urine at nanomolar levels by high-performance liquid chromatography with column switching. J Chromatogr 1993; 613:311-6. [PMID: 8491818 DOI: 10.1016/0378-4347(93)80147-v] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
An high-performance liquid chromatographic method with column switching for the detection of less than 4 ng of methotrexate in the urine of oncologic nurses is described. Urine samples were purified by solid-phase extraction on silica-bonded phenyl columns, eluting impurities with ethyl acetate. After elution from the column, the analyte was concentrated ten-fold, evaporating the solvent. On a strong anion-exchange column (Nucleosil 100 SB), methotrexate was separated from the remaining interfering substances, was then switched to a reversed-phase column (LiChrospher 100 RP-18e), and finally eluted by a linear gradient in a solvent system consisting of ammonium formate buffer (pH 2.7) and acetonitrile. Absorbance was monitored at 310 nm. This method has proved to be suitable for detecting traces of methotrexate in urine in order to individualize risks and to reduce further the occupational safety hazard for hospital personnel.
Collapse
Affiliation(s)
- R M Mader
- Department of Internal Medicine I, University of Vienna, Austria
| | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Mader RM, Steger GG, Rizovski B, Sieder AE, Locker G, Schiessel R, Jakesz R, Rainer H. Pharmakokinetik und Pharmakodynamik der Modulation von 5-Fluorouracil mittels Leucovorin. Eur Surg 1991. [DOI: 10.1007/bf02663227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Pecherstorfer M, Janisch S, Marosi C, Wogritsch C, Bosse C, Schratzberger W, Gerber E, Fortelny A, Lenzhofer R, Rainer H. [Pamidronate in the treatment of tumor-associated hypercalcemia]. Klin Wochenschr 1991; 69:690-5. [PMID: 1795492 DOI: 10.1007/bf01649438] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
After a 48-hour rehydration period 28 of 31 patients with cancer-associated hypercalcemia (serum calcium greater than or equal to 2.8 mmol/l) were treated intravenously with the bisphosphonate pamidronate. In three patients fluid repletion with 0.9% saline solution had already normalized serum calcium levels. Pamidronate was given in a single infusion on day 0, the dose of pamidronate adapted to the severity of hypercalcemia. If the serum calcium concentration was greater than or equal to 2.8 mmol/l on day 3, application of pamidronate was repeated. In all patients normocalcemia was restored; mean serum calcium decreased from 3.2 +/- 0.35 on day 0 to 2.15 +/- 0.32 on day 12. Hypercalcemia recurred in 11 patients, seven of these underwent pamidronate treatment according to the same therapeutical regimen. Normal calcium levels were attained in five cases. Side effects were of minor gravity: brief hyperthermia occurred in four patients and transient, asymptomatic hypocalcemia was noticed in nine cases.
Collapse
|
30
|
Alth G, Kolbabek H, Rainer H. Impact on survival of primary radiotherapy in locally advanced breast cancer (tumor stages T3/4, N +/- , M0). Radiother Oncol 1991; 21:69. [PMID: 1852923 DOI: 10.1016/0167-8140(91)90346-i] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
31
|
Rosskopf R, Rainer H, Giesecke D. [Purine and pyrimidine metabolites for the estimation of rumen metabolism: HPLC analysis in milk and blood plasma]. Arch Tierernahr 1991; 41:411-26. [PMID: 1888272 DOI: 10.1080/17450399109428482] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In milk and blood plasma samples of 6 German Simmental and 12 German Black and White heifers it was investigated, whether purine and pyrimidine compounds are suitable indicators of the microbial protein synthesis in the rumen. Therefore the secreted quantities in milk and the concentration in blood plasma are correlated with energy intake. The results indicated significant correlation coefficients for both the secretion quantity of allantoin in milk (r = 0.942) and the concentration of allantoin in blood plasma (r = 0.694). Other investigated compounds appeared more suitable for evaluating the mammary gland metabolism (uridine-lactose synthesis, pseudouridine-protein synthesis). In an experiment with 7 male castrated pigmy goats subjected to a four-day fasting period the decrease of plasma allantoin, which was already apparent after 12 hours of fasting, was closely correlated with the increase of plasma free fatty acids.
Collapse
Affiliation(s)
- R Rosskopf
- Institut für Physiologie, Physiologische Chemie und Ernährungsphysiologie, Tierärztliche Fakultät der Ludwig-Maximilians-Universität München
| | | | | |
Collapse
|
32
|
Abstract
Clear cell sarcoma of tendons and aponeuroses is a rare disorder which originates from migrated neural crest cells. It tends to local recurrences and dissemination and the prognosis has to be considered as poor. Based on a small series of patients, a wide surgical excision of the primary tumour or amputation are the therapies of choice. Radiotherapy might be of some value as an adjuvant treatment but radiotherapy and chemotherapy are of little value in the treatment of the advanced disease. Because of the lack of treatment alternatives we treated a 40-year-old female patient with disseminated clear cell sarcoma with interferon-alpha 2b (IFN-alpha 2b) perilesionally after several courses of systemic chemotherapy and radiotherapy had failed. After 4 months of therapy the patient came into a complete pathological remission which lasted for 17 months. A relapse of round cell sarcoma on both tumour sites was then noted. This outcome shows that IFN-alpha 2b was able to induce a complete remission in clear cell sarcoma and might have altered the natural course of the disease. IFN-alpha should be studied as adjuvant therapy after surgery of primary clear cell sarcoma and as a first-line palliative treatment in disseminated disease.
Collapse
Affiliation(s)
- G G Steger
- Department of Chemotherapy, University of Vienna, Austria
| | | | | | | | | | | |
Collapse
|
33
|
Mader RM, Steger GG, Moser K, Rainer H, Krenmayr P, Dittrich C. Instability of the anticancer agent etoposide under in vitro culture conditions. Cancer Chemother Pharmacol 1991; 27:354-60. [PMID: 1998995 DOI: 10.1007/bf00688857] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Degradation of etoposide is rapid under in vitro culture conditions. At pH 7.4 and 37 degrees C, the isomerisation of trans-etoposide to the inactive compound cis-etoposide has a half-life of 2 days in Dulbecco's modified Eagle's medium and results in the loss of 90% of the active drug within 1 week. As a consequence, prolonged incubations with etoposide in in vitro assays may lead to erroneous interpretations ignoring the real in vitro situation. The degradation is not influenced by organic compounds such as bovine serum albumin or amino acids but depends strongly on the pH value and, to a lesser degree, on the ionic strength of the medium. Therefore, we propose a mathematical correction based on the pH value so as to obtain the real exposure of cells to trans-etoposide during in vitro assays.
Collapse
Affiliation(s)
- R M Mader
- Department of Chemotherapy, University of Vienna, Austria
| | | | | | | | | | | |
Collapse
|
34
|
Jakesz R, Reiner G, Schemper M, Reiner A, Blijham G, Rainer H, Dittrich D, Spona J, Schutte B, Reynders M. Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results. Recent Results Cancer Res 1989; 115:180-5. [PMID: 2696031 DOI: 10.1007/978-3-642-83337-3_26] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- R Jakesz
- Abteilung für Chirurgie, Gynäkologie, Chemotherapie und Pathologie, Universität Wien, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Blöchl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, Steger G, Schüller J, Günther E, Proksch B, Ehninger G. Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol 1988; 24:1133-8. [PMID: 3416898 DOI: 10.1016/0277-5379(88)90119-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Mitoxantrone, a recent anthracenedione derivative, is a potentially useful drug for direct intraperitoneal (i.p.) application because of its high tissue binding and therapeutic index. We have carried out studies to establish maximum tolerated doses as well as pharmacokinetic studies with i.p. mitoxantrone in 21 patients (5 male, 16 female) with gastrointestinal (9), ovarian (6), unknown (2) and other (4) primary cancers and peritoneal carcinomatosis. Increasing doses (10-40 mg/m2) were given i.p. every 4 weeks. Five partial remissions (2-8+ months) and 7 stable disease courses (2-6+ months) were achieved. A reduction or disappearance of ascites was seen in an additional 3 patients. Severe toxicity (leucopenia) was observed in 4 patients only after 35 and 40 mg/m2 i.p. Pharmacokinetic analysis using high performance liquid chromatography yielded the following data: The mean ratio of area under curve peritoneal fluid to plasma was 1109. The peritoneal clearance rate was 680 ml/min and the mean disappearance half life was 13.1 h. Mean urinary excretion within 24 h was 0.42% of the i.p. dose. These data indicate that mitoxantrone is sequestered in the intraperitoneal tissue compartment and only slowly released. Based on the outcome of this phase I study we recommend phase II studies at a dose of 30 mg/m2 i.p., repeated every 3-4 weeks.
Collapse
Affiliation(s)
- B Blöchl-Daum
- Department of Chemotherapy, University of Vienna, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Rainer H. Impact of surgery on survival in locally advanced breast cancer. Lancet 1988; 1:295. [PMID: 2893100 DOI: 10.1016/s0140-6736(88)90370-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
37
|
Jakesz R, Dittrich C, Funovics J, Hofbauer F, Rainer H, Reiner G, Schemper M, Schiessel R, Starlinger M. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res 1988; 110:44-51. [PMID: 3043596 DOI: 10.1007/978-3-642-83293-2_6] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- R Jakesz
- I. Chirurgische Klinik, Universität Wien, Austria
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Eichler HG, Mader R, Blöchl-Daum B, Steger G, Rainer H. Poly(I).poly(C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study. Cancer Chemother Pharmacol 1987; 20:81-2. [PMID: 3621457 DOI: 10.1007/bf00252966] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Coupling of mitoxantrone, a new antitumor agent, to a macromolecular carrier system may improve the drug's selectivity of action and pharmacokinetic properties. We have studied in vitro binding of mitoxantrone to poly(I).poly(C), a macromolecular, double-stranded homoribopolymer, by equilibrium dialysis and high-performance liquid chromatography (HPLC). Results showed high binding affinity for mitoxantrone to poly(I).poly(C) (Kd = 1.05 X 10(-6) M), the calculated number of mitoxantrone-binding sites is 60 per molecule poly(I).poly(C). In view of the good tolerance in clinical studies, poly(I).poly(C) may thus be a useful drug carrier for mitoxantrone. A mitoxantrone:poly(I).poly(C) ratio of 1:30 (w/w) is recommended for therapeutic studies.
Collapse
|
39
|
Blöchl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, Steger G, Schüller J, Günther E, Proksch P, Ehninger G. Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. Onkologie 1987; 10:54-6. [PMID: 3295627 DOI: 10.1159/000216369] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Mitoxantrone, a recent anthracenedione derivative is a potentially useful drug for direct intraperitoneal (i.p.) application because of its high tissue-binding and therapeutic index. We have carried out studies to establish maximum tolerated doses as well as pharmacokinetic studies with i.p. mitoxantrone in 21 patients (5 male, 16 female) with gastrointestinal (9), ovarian (6), unknown (2) and other (4) primary cancers and peritoneal carcinomatosis. Increasing doses (10-40 mg/m2) were given i.p. every 4 weeks. Five partial remissions (2-8+ months) and 7 stable disease courses (2-6+ months) were achieved. A reduction or disappearance of ascites was seen in an additional 3 patients. Severe toxicity (leukopenia) was observed in 4 patients only after 35 mg/m2 and 40 mg/m2 i.p. Pharmacokinetic analysis using high-performance liquid chromatography yielded the following data: The mean ratio of area under curve peritoneal fluid to serum was 1,108. The peritoneal clearance ranged from 2 ml/min to 9,617 ml/min and the disappearance half-life from 0.6-28.9 h. Mean urinary excretion within 24 h was 0.42% of the i.p. dose. These data indicate that mitoxantrone is sequestered in the intraperitoneal tissue compartment and only slowly released. Based on the outcome of this phase-I study we recommend phase-II studies at a dose of 30 mg/m2 i.p., repeated every 3-4 weeks.
Collapse
|
40
|
Eichler HG, Blöchl-Daum B, Mader R, Rainer H, Steger G, Dittrich C, Moser K, Ehninger G. Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration. Chemotherapy 1987; 33:157-9. [PMID: 3595257 DOI: 10.1159/000238488] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Coupling of mitoxantrone (M), an intercalating cytostatic, to macromolecular polynucleotides may reduce side effects after direct intraperitoneal chemotherapy by interfering with systemic absorption of M. We have administered free M (30 mg/m2) or M mixed with poly(I).poly(C) (90 mg/m2) intraperitoneally to 5 patients with peritoneal carcinosis (cross-over study): peak plasma levels (HPLC assay) were 62 +/- 12 versus 28 +/- 4 ng/ml (p less than 0.0025), AUC0-24h were 583 +/- 126 versus 481 +/- 57 ng X h/ml (p less than 0.025). Coupling of M to poly(I).poly(C) seems to reduce M absorption after intraperitoneal administration.
Collapse
|
41
|
Mohsenipour I, Gabl M, Kostron H, Benedetto KP, Rainer H. [Depressed skull fractures in children]. Unfallchirurg 1987; 90:27-33. [PMID: 3563537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
42
|
Jakesz R, Dittrich C, Funovics J, Hofbauer F, Rainer H, Reiner G, Schemper M, Schiessel R, Starlinger M. [Adjuvant chemotherapy in patients with radical resection of stomach cancer: 5-year results of a prospective randomized study]. Wien Klin Wochenschr 1986; 98:824-30. [PMID: 3103336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
102 patients with operable gastric carcinoma were randomly allocated to untreated control, polychemotherapy, chemoimmunotherapy. At a median follow-up of 5 years, chemotherapy did not improve the overall survival rate. However, in certain subgroups, patients with lymphnode metastases and intestinal tumor type showed a significant survival benefit when treated with adjuvant chemotherapy. Furthermore, we found the site of first recurrence very closely related to the type of tumor histology. Regardless of the positive effect of chemotherapy in retrospective subset-analysis, we do not generally recommend the use of polychemotherapy in operable gastric carcinoma.
Collapse
|
43
|
Rainer H, Rasse M, Chiari FM. [An elastic obturator with a valve for the prosthetic treatment of maxillary resection defects]. Quintessenz 1986; 37:1711-7. [PMID: 3543996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
44
|
Kolb R, Kühnl-Brady K, Jakesz R, Moser K, Rainer H, Reiner G, Schemper M, Spona J. Results of a four-year prospective randomised study of operable breast cancer. J Cancer Res Clin Oncol 1986. [DOI: 10.1007/bf02580047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
Rainer H. Prospective randomized clinical trial: protoadjuvant chemotherapy vs. protoadjuvant radiotherapy in breast cancer stages T3/4, N+/-, M0. Wien Med Wochenschr 1985; 135:599-602. [PMID: 3913160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Patients selected for neo-adjuvant therapy in this trial suffered from breast cancer stages T3/4, N0/+, M0. Selected patients were stratified and assigned to either pre- and post-operative chemotherapy (tamoxifen, fluorouracil, vincristine, methotrexate, cyclophosphamide, mitoxantrone) or radiotherapy by randomization. This interim report deals with side-effects and response rates of pre-operative therapy only. For this subgroup from 41 centres, 67 patients have so far been accepted for protocol treatment. 36 received peri-operative chemotherapy and 31 perioperative radiotherapy. We have completed reports of 66 pre-operative chemotherapeutic cycles pointing out only low side-effects in spite of a combination consisting of 5 different cytotoxic agents plus hormonal therapy. It is remarkable that 79% had no hair loss and 74% no gastrointestinal side-effects; in the chemotherapy-group 24 patients so far have been operated. Response rates were as follows: 1 (4%) complete remission, 9 (38%) partial remission, 7 (29%) minor response, 2 (8%) no response and 2 (8%) progression. In 2 patients response could not be determined. In the perioperative radiotherapy-group 10 patients have been operated with similar response rates. It is interesting to note, that both therapies influenced receptor values in different ways: Chemotherapy decreased receptor values, whereas radiotherapy insignificantly increased them. The purpose of this study is to establish a rational base for post-operative cytotoxic treatment of patients as only patients who objectively respond to preoperative treatment are likely to benefit from postoperative drug administration. The study is open for enrollment until a total of 200 patients is reached.
Collapse
|
46
|
Kolb R, Jakesz R, Moser K, Rainer H, Reiner G, Spona J, Schemper M. 231. Vier-Jahresergebnisse einer prospektiv randomisierten Studie beim operablen Mammacarcinom. Langenbecks Arch Surg 1985. [DOI: 10.1007/bf01836830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Salzer H, Gitsch E, Dittrich C, Sevelda P, Karrer K, Schemper M, Stempel-Smekal G, Langer M, Wagner G, Rainer H. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients]. Geburtshilfe Frauenheilkd 1985; 45:761-8. [PMID: 3908214 DOI: 10.1055/s-2008-1036132] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
From June 1980 to December 1982 164 patients with ovarian cancer stage III and IV were randomized into the three-legged Austrian Ovarian Cancer Study. A new polychemotherapy, known as the "changing-scheme" (adriamycin/cisplatinum--vincristine/cyclophosphamide--high dose methotrexate), developed in Vienna, was compared with adriamycin/cyclophosphamide and adriamycin/cisplatinum. The risk factors were stratified by means of special computer-assisted randomization. The first study evaluation in 1982 showed a significant advantage for the changing-scheme with regard to recurrence-free interval and survival (Mantel test: p less than 0.01, Breslow test: p less than 0.03). No difference was found between the combinations of adriamycin/cyclophosphamide and adriamycin/cisplatinum. At the second study evaluation in June 1984 the differences previously observed were no longe present to the same significant extent. The changing-scheme continued to be superior for the subgroups of patients with highly differentiated tumors, without ascites, with larger postoperative tumor burden and with liver metastases. The use of this therapy is be recommended for women with advanced ovarian cancer, especially in consideration of the much lower toxicity caused by the less frequent cisplatinum administrations as compared to the adriamycin/cisplatinum combination.
Collapse
|
48
|
Wunderlich M, Schiessel R, Rainer H, Rauhs R, Kovats E, Schemper M, Dittrich C, Micksche M, Sedlacek HH. Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure. Br J Surg 1985; 72 Suppl:S107-10. [PMID: 3899250 DOI: 10.1002/bjs.1800721352] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
After radical surgery for colorectal cancer, 178 patients with a Dukes' B or C tumour were randomly assigned to one of three groups: A, controls (n = 62); B, chemotherapy (n = 59); C, immunotherapy (n = 57). Randomization criteria (age, sex, Dukes' stage, localization of tumour, operative procedure) were evenly distributed throughout the groups. After a median observation time of 30 months, statistical analyses were performed: survival and probability to be free of recurrence was described by Kaplan-Meier estimates of the survival function; for comparison of these survival functions, Breslow's test was used. Overall analyses show no benefit in the treatment group compared to controls. Separate analyses by Dukes' stages showed that in patients with Dukes' C tumours the probability of survival 40 months after surgery was 72 per cent in group C, 51 per cent in group B, and 33 per cent in group A. The differences between groups C and A, and B and A were statistically significant (P less than 0.02 and P less than 0.03 respectively). For a Dukes' C tumour the probability to be free of distant metastases at 30 months after surgery was 80 per cent in group B, 68 per cent in group C and 52 per cent in group A. Also for a Dukes' C tumour the probability to be free of liver metastases at 21 months after surgery was 83 per cent in group B, 81 per cent in group C, and 54 per cent in group A (significant differences: B-A and C-A P less than 0.04 for both). There was no influence on the estimated incidence of local recurrences for stage Dukes' C. Patients with a Dukes' B tumour did not benefit from either of the adjuvant therapy schemes.
Collapse
|
49
|
Mouridsen HT, Cornbleet M, Stuart-Harris R, Smith I, Coleman R, Rubens R, McDonald M, Rainer H, van Oosterom A, Smyth J. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study. Invest New Drugs 1985; 3:139-48. [PMID: 4019118 DOI: 10.1007/bf00174161] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Mitoxantrone (Novantrone; dihydroxyanthracenedione) is a substituted anthraquinone with a spectrum of activity similar to doxorubicin in experimental tumors. One hundred and seventy three patients with advanced breast cancer and no prior cytotoxic therapy for advanced disease entered a phase II study of mitoxantrone, 14 mg/m2 i.v. repeated every 3 weeks. At the time of this analysis 116 patients were evaluable. Eight patients achieved a complete response and 27 a partial response, the overall response rate being 30% (95% confidence limits: 22-39%). The median time until response was recorded was 15 weeks. The median duration of response was 74+ weeks and the median time to progression or death for all 116 patients was 22+ weeks. Mitoxantrone was well tolerated with myelosuppression as the dose-limiting toxicity. The most frequent non-haematological toxicities were nausea and vomiting (65%) but they were rarely severe. Total alopecia occurred in only 6% of the patients. Four patients developed clinically significant evidence of cardiotoxicity after cumulative mitoxantrone doses of 174-256 mg/m2. Thus, mitoxantrone offers comparable efficacy and less acute toxicity than the most active single agents currently available in the treatment of advanced breast cancer.
Collapse
|
50
|
Jakesz R, Dittrich C, Hanusch J, Kolb R, Lenzhofer R, Moser K, Rainer H, Reiner G, Schemper M, Spona J. Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy. Ann Surg 1985; 201:305-10. [PMID: 3977430 PMCID: PMC1250669 DOI: 10.1097/00000658-198503000-00008] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Estrogen (ER), progesterone (PgR), and androgen (AR) receptors were measured in two simultaneous or subsequent specimens taken each from 259 patients with breast cancer. We studied in 182 patients results from receptor assays, either from one tumor or from the primary tumor, and a lymph node metastasis, and in 77 sequential biopsies with or without intervening therapy. All assays were performed in a single laboratory, considering 10 fmol/mg cytosol protein bound ligand as receptor positive. The concordance rate in simultaneous ER assays was 85%; however, we found a considerable high discordance rate for PgR in primary tumor and lymph node metastasis (25%). The overall discordance rate in sequential biopsies for ER was 38% and for PgR 25%. This discordance rate was primarily dependent on the receptor quality of the first assay (ER+: 50%, ER-: 24%, PgR+: 68%, PgR-: 9%). Considering only the ER+ and PgR+ cases, we found the greatest discordance rate in the patients having endocrine treatment following the first biopsy (55% and 84%, respectively). We conclude that the receptor status of one tumor biopsy is highly representative for other tumor or lymph node biopsies. Because of the high discordance rate of primarily receptor + cases in subsequent recurrences, the receptor quality of these lesions should be analyzed whenever possible.
Collapse
|